{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:00:37Z","timestamp":1794013237233,"version":"4.8.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hemolytic disease of the fetus and newborn (HDFN) is a condition due to maternal blood group antibodies targeting antigens in fetal red blood cells, with significant prenatal\/perinatal morbidity and mortality. Severe HDFN cases are often associated with alloimmunization against Rhesus D (RhD) or Kell antigens. Information about HDFN epidemiology and treatment in Latin American countries is limited. This review aims to identify and synthesize the available evidence on the epidemiology and management of HDFN in this region.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In July 2023, EMBASE, PubMed, LILACS, and other databases were searched for articles reporting epidemiology, treatment, prenatal and perinatal outcomes, and patient journey of HDFN cases in Latin American countries. A snowball search of cross-references and gray literature complemented the initial search. Publications in English, Spanish, and Portuguese were reviewed. Data were extracted using a defined template and charted in tables.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We reviewed five guidelines and 19 observational studies from Brazil, Chile, Mexico, Argentina, Colombia, Panam\u00e1, Paraguay, and Peru. HDFN due to Rh alloimmunization ranged from 0.5 to 5 per 1000 live births, and anti-D remains the most frequent alloantibody type for severe HDFN. The perinatal mortality rate of HDFN is approximately 1.3\u20131.6 per 100,000 live births, and fetal deaths can reach 30% among patients treated with intrauterine transfusions. Up to 47% of alloimmunized pregnancies were referred to reference centers only during the third trimester. About 60% of eligible pregnancies received anti-D IgG prophylaxis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Although estimates in LATAM countries are scarce and lack standardized measures, we observed that the incidence, morbidity, and mortality of HDFN in this region are problematic. RhD alloimmunization was reported in approximately up to 70% of severe HDFN cases, despite anti D HDFN being largely preventable.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12884-024-07044-3","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T06:35:17Z","timestamp":1734676517000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hemolytic disease of the fetus and newborn and Rhesus alloimmunization in Latin American countries: a scoping review"],"prefix":"10.1186","volume":"24","author":[{"given":"M\u00e1rio Dias Corr\u00eaa","family":"J\u00fanior","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador Espino y","family":"Sosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milene","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lais","family":"do Carmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato Watanabe","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Kanevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"issue":"2","key":"7044_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/vox.12265","volume":"109","author":"M de Haas","year":"2015","unstructured":"de Haas M, Thurik FF, Koelewijn JM, van der Schoot CE. Haemolytic disease of the fetus and newborn. Vox Sang. 2015;109(2):99\u2013113.","journal-title":"Vox Sang"},{"issue":"7","key":"7044_CR2","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1080\/17474086.2017.1331124","volume":"10","author":"IMC Ree","year":"2017","unstructured":"Ree IMC, Smits-Wintjens V, van der Bom JG, van Klink JMM, Oepkes D, Lopriore E. Neonatal management and outcome in alloimmune hemolytic disease. Expert Rev Hematol. 2017;10(7):607\u201316.","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"7044_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12884-022-05329-z","volume":"23","author":"DP de Winter","year":"2023","unstructured":"de Winter DP, Kaminski A, Tjoa ML, Oepkes D. Hemolytic disease of the fetus and newborn: systematic literature review of the antenatal landscape. BMC Pregnancy Childbirth. 2023;23(1):12.","journal-title":"BMC Pregnancy Childbirth"},{"issue":"1","key":"7044_CR4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1182\/asheducation-2015.1.146","volume":"2015","author":"M Delaney","year":"2015","unstructured":"Delaney M, Matthews DC. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. Hematology. 2015;2015(1):146\u201351.","journal-title":"Hematology"},{"issue":"2","key":"7044_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00431-022-04724-0","volume":"182","author":"DP De Winter","year":"2023","unstructured":"De Winter DP, Hulzebos C. Van 't Oever RM, De Haas M, Verweij EJ, Lopriore E: History and current standard of postnatal management in hemolytic disease of the fetus and newborn. Eur J Pediatr. 2023;182(2):489\u2013500.","journal-title":"Eur J Pediatr"},{"issue":"2","key":"7044_CR6","doi-asserted-by":"publisher","first-page":"F83","DOI":"10.1136\/adc.2005.076794","volume":"92","author":"NA Murray","year":"2007","unstructured":"Murray NA, Roberts IA. Haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed. 2007;92(2):F83-88.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"7044_CR7","unstructured":"Hall V, Vadakekut ES, Avulakunta ID. Hemolytic Disease of the Fetus and Newborn. [Updated 2024 Jun 7]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557423\/."},{"issue":"3","key":"7044_CR8","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1097\/AOG.0000000000002528","volume":"131","author":"ACOG Practice Bulletin No","year":"2018","unstructured":"ACOG Practice Bulletin No. 192: Management of Alloimmunization During Pregnancy. Obstet Gynecol. 2018;131(3):e82\u201390.","journal-title":"Obstet Gynecol"},{"key":"7044_CR9","unstructured":"Dean L: blood groups and red cell antigens. Bethesda (MD): National Center for Biotechnology Information (US); 2005. Chapter 4, Hemolytic disease of the newborn. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK2266\/."},{"issue":"Suppl 1","key":"7044_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/pr.2013.208","volume":"74","author":"VK Bhutani","year":"2013","unstructured":"Bhutani VK, Zipursky A, Blencowe H, Khanna R, Sgro M, Ebbesen F, Bell J, Mori R, Slusher TM, Fahmy N, et al. Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels. Pediatr Res. 2013;74(Suppl 1):86\u2013100.","journal-title":"Pediatr Res"},{"issue":"1","key":"7044_CR11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.siny.2014.12.001","volume":"20","author":"A Zipursky","year":"2015","unstructured":"Zipursky A, Bhutani VK. Impact of Rhesus disease on the global problem of bilirubin-induced neurologic dysfunction. Semin Fetal Neonatal Med. 2015;20(1):2\u20135.","journal-title":"Semin Fetal Neonatal Med"},{"issue":"7","key":"7044_CR12","doi-asserted-by":"publisher","first-page":"e0235807","DOI":"10.1371\/journal.pone.0235807","volume":"15","author":"V Pegoraro","year":"2020","unstructured":"Pegoraro V, Urbinati D, Visser GHA, Di Renzo GC, Zipursky A, Stotler BA, Spitalnik SL. Hemolytic disease of the fetus and newborn due to Rh(D) incompatibility: A preventable disease that still produces significant morbidity and mortality in children. PLoS ONE. 2020;15(7):e0235807.","journal-title":"PLoS ONE"},{"issue":"1","key":"7044_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L. Scoping studies: towards a methodological framework. Int J Social Res Methodology. 2005;8(1):19\u201332.","journal-title":"Int J Social Res Methodology"},{"issue":"7","key":"7044_CR14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467\u201373.","journal-title":"Ann Intern Med"},{"key":"7044_CR15","first-page":"15","volume":"34","author":"C Br\u00edtez","year":"2007","unstructured":"Br\u00edtez C, Samudio-D G. Costo ocasionado por la enfermedad hemol\u00edtica del reci\u00e9n nacido por incompatibilidad Rh vs costo de la profilaxis. Pediatr\u00eda (Asunci\u00f3n). 2007;34:15\u201323.","journal-title":"Pediatr\u00eda (Asunci\u00f3n)"},{"key":"7044_CR16","unstructured":"Campos MVX. Correla\u00e7\u00e3o entre t\u00edtulos de anticorpos anti-D e desfecho gestacional adverso em gestantes com antecedente de doen\u00e7a hemol\u00edtica perinatal. S\u00e3o Paulo: Universidade de S\u00e3o Paulo; 2016."},{"key":"7044_CR17","unstructured":"Mamani Choquepata RS. Caracter\u00edsticas cl\u00ednicas y laboratoriales de recien nacidos con enfermedad hemol\u00edtica por incompatibilidad de grupo sanguineo abo o de factor rh en el Hospital Regional Honorio Delgado Espinoza en los a\u00f1os 2008\u20132012. Master thesis. Arequipa: Universidad Nacional de San Agust\u00edn; 2013."},{"issue":"5","key":"7044_CR18","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1590\/1806-9282.20220047","volume":"68","author":"\u00daR Duete","year":"2022","unstructured":"Duete \u00daR, Brunetta DM, Araujo J\u00fanior E, Tonni G, Carvalho FHC. Maternal-fetal alloimmunization: perinatal outcomes in a reference hospital in Northeastern Brazil. Rev Assoc Med Bras. 2022;68(5):670\u20134.","journal-title":"Rev Assoc Med Bras"},{"issue":"6","key":"7044_CR19","first-page":"411","volume":"91","author":"C Durango-S\u00e1nchez","year":"2023","unstructured":"Durango-S\u00e1nchez C, Mart\u00ednez-S\u00e1nchez LM, V\u00e1squez-Estrada V, Jaramillo-Jaramillo LI, Zapata-Cardona LM, Campo-Campo MN. Descripci\u00f3n de una poblaci\u00f3n de embarazadas con incompatibilidad Rh (D). Ginecol Obstet Mex. 2023;91(6):411\u20136.","journal-title":"Ginecol Obstet Mex"},{"issue":"9","key":"7044_CR20","doi-asserted-by":"publisher","first-page":"e8802","DOI":"10.25248\/reas.e8802.2021","volume":"13","author":"AP Fernandes","year":"2021","unstructured":"Fernandes AP, de Oliveira Soeiro CM, Ribeiro FA, da Silva RK, de Oliveira GP. Preval\u00eancia de isoimuniza\u00e7\u00e3o Rh materna em maternidade p\u00fablica do Amazonas entre 2018 e 2020. Rev Eletr\u00f4nica Acervo Sa\u00fade. 2021;13(9):e8802\u2013e8802.","journal-title":"Rev Eletr\u00f4nica Acervo Sa\u00fade"},{"key":"7044_CR21","unstructured":"Lewis VV. Impacto en el diagn\u00f3stico temprano de la enfermedad hemol\u00edtica del reci\u00e9n nacido en neonatos mayores de 2 kg mediante el tamizaje de la bilirrubinas por m\u00e9todo transcut\u00e1neo. Rev Ped Panam\u00e1. 2018;47(1):20\u201331."},{"key":"7044_CR22","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1590\/S0102-311X2008000300014","volume":"24","author":"G Lobato","year":"2008","unstructured":"Lobato G, Reichenheim ME, Coeli CM. Sistema de informa\u00e7\u00f5es hospitalares do sistema \u00fanico de sa\u00fade (SIH-SUS): uma avalia\u00e7\u00e3o preliminar do seu desempenho no monitoramento da doen\u00e7a hemol\u00edtica perinatal Rh (D). Cad Sa\u00fade P\u00fablica. 2008;24:606\u201314.","journal-title":"Cad Sa\u00fade P\u00fablica"},{"key":"7044_CR23","unstructured":"Lobo GAR. O desfecho perinatal da aloimuniza\u00e7\u00e3o eritrocit\u00e1ria n\u00e3o-relacionada ao ant\u00edgeno RhD. Master thesis. S\u00e3o Paulo: Universidade Federal de S\u00e3o Paulo \u2013 Escola Paulista de Medicina; 2007."},{"issue":"2","key":"7044_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ejogrb.2006.06.007","volume":"132","author":"LM Nardozza","year":"2007","unstructured":"Nardozza LM, Camano L, Moron AF, Chinen PA, Torloni MR, Cordioli E, Ara\u00fajo Junior E. Perinatal mortality in Rh alloimmunized patients. Eur J Obstet Gynecol Reprod Biol. 2007;132(2):159\u201362.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"7044_CR25","unstructured":"Osanan GC. An\u00e1lise multivariada dos fatores determinantes da mortalidade perinatal de fetos submetidos \u00e0 transfus\u00e3o sangu\u00ednea intrautero por anemia decorrente da isoimuniza\u00e7\u00e3o materna. Master thesis. Belo Horizonte: Universidade Federal de Minas Gerais; 2010."},{"key":"7044_CR26","doi-asserted-by":"publisher","first-page":"340","DOI":"10.4067\/s0717-75262019000500340","volume":"84","author":"DT Pinochet","year":"2019","unstructured":"Pinochet DT, Aguilera PS, Cisternas OD, Terra VR, Fuente GSDL, Rodr\u00edguez A. JG: Transfusi\u00f3n intrauterina: tratamiento de anemia fetal severa en el Centro de Referencia Perinatal Oriente. Rev Chil Obstet Ginecol. 2019;84:340\u20135.","journal-title":"Rev Chil Obstet Ginecol"},{"issue":"9","key":"7044_CR27","first-page":"469","volume":"78","author":"LJ Ram\u00edrez-Robles","year":"2010","unstructured":"Ram\u00edrez-Robles LJ, G\u00f3mez-Partida G, Guevara-Rubio G, Vel\u00e1zquez-G\u00f3mez L. Intrauterine transfusi\u00f3n in alloimmunization Rh in M\u00e9xico 1987\u20132008. Ginecol Obstet Mex. 2010;78(9):469\u201377.","journal-title":"Ginecol Obstet Mex"},{"key":"7044_CR28","doi-asserted-by":"crossref","unstructured":"Rold\u00e1n-Isaza M, Vergara-Y\u00e1nez D, Hern\u00e1ndez-Mart\u00ednez A, et al. Clinical and epidemiological profile of patients with hemolytic anemia of the newborn treated in a university hospital, Medellin, Colombia, 2014-2018. Acta Pediatr Mex. 2023;44(2):109\u201319.","DOI":"10.18233\/apm.v44i2.2407"},{"issue":"2","key":"7044_CR29","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1590\/S0103-05822009000200008","volume":"27","author":"CAM S\u00e1","year":"2009","unstructured":"S\u00e1 CAM, Santos MCP, de Carvalho M, Moreira MEL. Eventos adversos associados \u00e0 exsangu\u00edneotransfus\u00e3o na doen\u00e7a hemol\u00edtica perinatal: experi\u00eancia de dez anos. Rev Paulista Pediatria. 2009;27(2):168\u201372.","journal-title":"Rev Paulista Pediatria"},{"key":"7044_CR30","unstructured":"Seidl V. Doen\u00e7a hemol\u00edtica perinatal: fatores de risco e abordagem terap\u00eautica. Doctoral Dissertation. Rio de Janeiro: Funda\u00e7\u00e3o Oswaldo Cruz Instituto Nacional de Sa\u00fade da Mulher, da Crian\u00e7a e do Adolescente Fernandes Figueira; 2013."},{"key":"7044_CR31","doi-asserted-by":"publisher","first-page":"447","DOI":"10.4067\/S0717-75262013000600008","volume":"78","author":"A Sep\u00falveda-Mart\u00ednez","year":"2013","unstructured":"Sep\u00falveda-Mart\u00ednez A, Figueroa PJ, Rencoret PG, Parra-Cordero M. Resultado neonatal e infantil de ni\u00f1os con y sin transfusi\u00f3n intrauterina por isoinmunizaci\u00f3n Rh durante el embarazo. Rev Chil Obstet Ginecol. 2013;78:447\u201350.","journal-title":"Rev Chil Obstet Ginecol"},{"key":"7044_CR32","first-page":"1","volume":"101","author":"O Torres","year":"2011","unstructured":"Torres O, Endara A, Rey P. P-247 Antenatal Use of High-Dose Intravenous Gammaglobulin for the Treatment of Severe Hemolytic Disease of the Newborn. Vox Sang. 2011;101:1\u2013352.","journal-title":"Vox Sang"},{"key":"7044_CR33","unstructured":"Villaschi JF. Avalia\u00e7\u00e3o da evolu\u00e7\u00e3o dos rec\u00e9m-nascidos com doen\u00e7a hemol\u00edtica perinatal por aloimuniza\u00e7\u00e3o materna, submetidos e n\u00e3o \u00e0 transfus\u00e3o intrauterina.\u00a0Master thesis. Belo Horizonte: Universidade Federal de Minas Gerais; 2012."},{"issue":"2","key":"7044_CR34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.18233\/apm.v44i2.2407","volume":"44","author":"MR Isaza","year":"2023","unstructured":"Isaza MR, Y\u00e1nez DV, Mart\u00ednez AH, Quintero NM, G\u00e1zquez Mdl\u00c1R, S\u00e1nchez LMM. Perfil cl\u00ednico y epidemiol\u00f3gico de los pacientes con enfermedad hemol\u00edtica del reci\u00e9n nacido atendidos en un hospital universitario, Medell\u00edn, Colombia, 2014\u20132018. Acta Ped M\u00e9xico. 2023;44(2):109\u201319.","journal-title":"Acta Ped M\u00e9xico"},{"key":"7044_CR35","doi-asserted-by":"publisher","unstructured":"Schettini J, Heraclio S, Coutinho I, Torres L. P0122 - Maternal RhD alloimmunization: a new antenatal anti-D prophylaxis. In: Poster Presentations. Int J Gynecol Obstet; 2015;(131):E314-E607. https:\/\/doi.org\/10.1016\/S0020-7292(15)30004-7.","DOI":"10.1016\/S0020-7292(15)30004-7"},{"issue":"17","key":"7044_CR36","doi-asserted-by":"publisher","first-page":"e45101724240","DOI":"10.33448\/rsd-v10i17.24240","volume":"10","author":"EE Macedo","year":"2021","unstructured":"Macedo EE, Lima CB, Coelho AVD, de Sousa Carmo RR, da Cruz Nascimento CL, Amaral AB, Oliveira AT. Interna\u00e7\u00f5es hospitalares por doen\u00e7a hemol\u00edtica do rec\u00e9m-nascido no estado do Piau\u00ed, entre 2014 e 2019. Res Soc Development. 2021;10(17):e45101724240\u2013e45101724240.","journal-title":"Res Soc Development"},{"key":"7044_CR37","unstructured":"Pacheco CAMS. Doen\u00e7a hemol\u00edtica perinatal RhD: Um problema de sa\u00fade p\u00fablica no Brasil. Doctoral dissertation. Rio de Janeiro: Funda\u00e7\u00e3o Oswaldo Cruz Instituto Nacional de Sa\u00fade da Mulher e da Crian\u00e7a Fernandes Figueira; 2013."},{"issue":"3","key":"7044_CR38","first-page":"31","volume":"10","author":"VM Vindas","year":"2020","unstructured":"Vindas VM, Mar\u00edn EP, Vives SC, Pe\u00f1aranda GF. Hidrops Fetal por aloinmunizaci\u00f3n RH tratado mediante transfusiones intrauterinas seriadas. Rev Cl\u00edn Esc Med UCR-HSJD. 2020;10(3):31\u20137.","journal-title":"Rev Cl\u00edn Esc Med UCR-HSJD"},{"issue":"4","key":"7044_CR39","doi-asserted-by":"publisher","first-page":"643","DOI":"10.7705\/biomedica.5930","volume":"41","author":"M P\u00e1ez","year":"2021","unstructured":"P\u00e1ez M, Jim\u00e9nez M, Corredor A. Enfermedad hemol\u00edtica del feto y del reci\u00e9n nacido por aloanticuerpos contra el ant\u00edgeno M. Biomedica. 2021;41(4):643\u201350.","journal-title":"Biomedica"},{"key":"7044_CR40","unstructured":"DATASUS. Minist\u00e9rio da Sa\u00fade. Departamento de inform\u00e1tica do SUS. Dispon\u00edvel em http:\/\/www.datasus.gov.br."},{"key":"7044_CR41","unstructured":"S\u00e1 CAM. Doen\u00e7a hemol\u00edtica perinatal pelo fator Rh: experi\u00eancia de 10 anos do Instituto Fernandes Figueira. Master thesis. Rio de Janeiro: Instituto Fernandes Figueira; 2006."},{"issue":"2","key":"7044_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.xagr.2023.100203","volume":"3","author":"D Yu","year":"2023","unstructured":"Yu D, Ling LE, Krumme AA, Tjoa ML, Moise KJ Jr. Live birth prevalence of hemolytic disease of the fetus and newborn in the United States from 1996 to 2010. AJOG Glob Rep. 2023;3(2): 100203.","journal-title":"AJOG Glob Rep"},{"key":"7044_CR43","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12884-014-0411-1","volume":"14","author":"TM Fyfe","year":"2014","unstructured":"Fyfe TM, Ritchey MJ, Taruc C, Crompton D, Galliford B, Perrin R. Appropriate provision of anti-D prophylaxis to RhD negative pregnant women: a scoping review. BMC Pregnancy Childbirth. 2014;14:411.","journal-title":"BMC Pregnancy Childbirth"},{"issue":"5","key":"7044_CR44","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3390\/jcm13051362","volume":"13","author":"D Pares","year":"2024","unstructured":"Pares D, Pacheco G, Lobo GAR, Araujo J\u00fanior E. Intrauterine Transfusion for Rhesus Alloimmunization: A Historical Retrospective Cohort from A Single Reference Center in Brazil. J Clin Med. 2024;13(5):1362.","journal-title":"J Clin Med"},{"issue":"1","key":"7044_CR45","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/trf.17176","volume":"63","author":"SJ Jansen","year":"2023","unstructured":"Jansen SJ, Ree IMC, Broer L, de Winter D, de Haas M, Bekker V, Lopriore E. Neonatal sepsis in alloimmune hemolytic disease of the fetus and newborn: A retrospective cohort study of 260 neonates. Transfusion. 2023;63(1):117\u201324.","journal-title":"Transfusion"},{"issue":"1","key":"7044_CR46","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/trf.15635","volume":"60","author":"B Gudlaugsson","year":"2020","unstructured":"Gudlaugsson B, Hjartardottir H, Svansdottir G, Gudmundsdottir G, Kjartansson S, Jonsson T, Gudmundsson S, Halldorsdottir AM. Rhesus D alloimmunization in pregnancy from 1996 to 2015 in Iceland: a nation-wide population study prior to routine antenatal anti-D prophylaxis. Transfusion. 2020;60(1):175\u201383.","journal-title":"Transfusion"},{"issue":"11","key":"7044_CR47","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1111\/trf.14262","volume":"57","author":"G Bollason","year":"2017","unstructured":"Bollason G, Hjartardottir H, Jonsson T, Gudmundsson S, Kjartansson S, Halldorsdottir AM. Red blood cell alloimmunization in pregnancy during the years 1996\u20132015 in Iceland: a nation-wide population study. Transfusion. 2017;57(11):2578\u201385.","journal-title":"Transfusion"},{"issue":"24","key":"7044_CR48","first-page":"00255","volume":"S2531\u20131379","author":"J Silva","year":"2024","unstructured":"Silva J, de Souza AM, Rosario FMD, Pinto LC. Pregnant women\u2019s knowledge and clinical management of hemolytic disease of the fetus and newborn in Para. Brazil Hematol Transfus Cell Ther. 2024;S2531\u20131379(24):00255\u201364.","journal-title":"Brazil Hematol Transfus Cell Ther"},{"issue":"3","key":"7044_CR49","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/vox.12883","volume":"115","author":"YM Slootweg","year":"2020","unstructured":"Slootweg YM, Walg C, Koelewijn JM, Van Kamp IL, De Haas M. Knowledge, attitude and practices of obstetric care providers towards maternal red-blood-cell immunization during pregnancy. Vox Sang. 2020;115(3):211\u201320.","journal-title":"Vox Sang"},{"issue":"11","key":"7044_CR50","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/17474086.2022.2138853","volume":"15","author":"RM van \u2019t Oever","year":"2022","unstructured":"van \u2019t Oever RM, Zwiers C, de Winter D, de Haas M, Oepkes D, Lopriore E, Verweij EJJ. Identification and management of fetal anemia due to hemolytic disease. Expert Rev Hematol. 2022;15(11):987\u201398.","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"7044_CR51","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/pd.5355","volume":"38","author":"C Zwiers","year":"2018","unstructured":"Zwiers C, Oepkes D, Lopriore E, Klumper FJ, de Haas M, van Kamp IL. The near disappearance of fetal hydrops in relation to current state-of-the-art management of red cell alloimmunization. Prenat Diagn. 2018;38(12):943\u201350.","journal-title":"Prenat Diagn"},{"issue":"2","key":"7044_CR52","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/ijgo.13459","volume":"152","author":"GHA Visser","year":"2021","unstructured":"Visser GHA, Thommesen T, Di Renzo GC, Nassar AH, Spitalnik SL. FIGO\/ICM guidelines for preventing Rhesus disease: A call to action. Int J Gynaecol Obstet. 2021;152(2):144\u20137.","journal-title":"Int J Gynaecol Obstet"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-024-07044-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-024-07044-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-024-07044-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T07:05:06Z","timestamp":1734678306000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-024-07044-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["7044"],"URL":"https:\/\/doi.org\/10.1186\/s12884-024-07044-3","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"17 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MDCJ and SES have no conflict of interest to declare. MF is an employee of CTI Clinical Trial and Consulting Services, a contract research organization that provides consultancy services to J&J and other companies. LC, RWO, and GK are employees of Janssen.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"830"}}